Showing 671-680 of 3545 results for "".
Acne Update: A Review of New Guidelines, Treatment Advances, and Drugs in the Pipeline
https://practicaldermatology.com/topics/general-topics/acne-update-a-review-of-new-guidelines-treatment-advances-and-drugs-in-the-pipeline/18773/Linda Stein Gold, MD talks to DermTube Journal Club Host Joshua Zeichner, MD about the new acne treatment guidelines recently published in the Journal of the American Academy of Dermatology. She discusses the process of developing the guidelines and highlights some of what's new, such as new, limiteOptimizing Absorption of Oral Isotretinoin
https://practicaldermatology.com/columns/clinical-focus-1/optimizing-absorption-of-oral-isotretinoin/23066/An update on lidose-isotretinoin and the ability to enhance absorption in the absence of high-fat meals.Rosacea Unveiled: A YoungMD Connect Open Discussion with Dr. Corey Hartman
https://practicaldermatology.com/youngmd-connect/wrap-ups/rosacea-unveiled-a-youngmd-connect-open-discussion-with-dr-corey-hartman/27168/In his YoungMD Connect virtual session on the topic of rosacea, Dr. Corey Hartman shared extensive experience with the eager viewing audience. Topics discussed included treating patients with rosacea, including those with skin of color, as well as clinical pearls on diagnosing and managing this commEyeing a Treatment for Syringoma
https://practicaldermatology.com/series/scientifically-speaking/eyeing-a-treatment-for-syringoma/20112/Listen as Joel L. Cohen, MD describes early evidence for the use of nano pulse stimulation to treat syringoma, a notoriously challenging target.Scientifically Speaking: Effective By Design with Josh Makower, MD
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-effective-by-design-with-josh-makower-md/20106/Josh Makower, MD has been at the forefront of several medical innovations. Listen in as he describes his approach and discusses his latest product with host Joel L. Cohen, MD. The Avéli device from Revelle Aesthetics is FDA-cleared to reduce cellulite in the buttocks and thighs temporarily.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneAre Exosomes the Next Big Thing?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/are-exosomes-the-next-big-thing/20090/Dr. Farris, co-founder (with Dr. Ted Lain) of the Science of Skincare Summit, summarizes key points from her recent article on exosomes and their potential applications for topical skincare? Are they the next big thing? Watch to find out!Ensuring Excellent Care Across LGBTQ and Sexual Minority Patients
https://practicaldermatology.com/topics/practice-management/ensuring-excellent-care-across-lgbtq-and-sexual-minority-patients/20077/The session on LGBTQ and sexual gender minority health covered a range of topics including both clinical care as well as terminology, structures, and framework. Klint Peebles, MD talks about the importance of providing excellent dermatologic care as patients face disparities and challenges in accessContact Derm and AD Updates
https://practicaldermatology.com/conferences/maui-derm-2022/contact-derm-and-ad-updates/20052/Matthew Zirwas, MD reviews allergens that have made the list of Allergen of the Year over the program's 20-year history and what dermatologists should know about these allergens. He also provides an overview of his approach to diagnosing and treating atopic dermatitis.The Expanding Role for PD-1 Inhibitors for NMSCs
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-expanding-role-for-pd-1-inhibitors-for-nmscs/19937/The pool of potential patients that could be treated with PD-1 inhibitors is growing. Todd Schlesinger, MD discusses how these drugs may be used to treat a greater number of patients with NMSCs and addresses side effects and their management.